Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review.

  title={Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review.},
  author={Frank I Scott and Gary R. Lichtenstein},
  journal={Current treatment options in gastroenterology},
  volume={14 1},
OPINION STATEMENT Monoclonal antibody therapy directed against tumor necrosis factor-alpha (anti-TNFs) has revolutionized the care of patients with Crohn's disease and ulcerative colitis. These large proteins are potentially immunogenic. Early clinical trials demonstrated an association with both serum concentrations of these agents as well as the presence of antidrug antibodies generated by the host with loss of response. More recent research has provided further evidence to confirm the impact… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS


Publications referenced by this paper.
Showing 1-10 of 54 references

Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2015

charac - teristics of skin lesions associated with anti - tumor necrosis factor therapy in patients with inflammatory bowel disease : a cohort study

I Cleynen, WV Moerkercke, T Billiet
Ann Intern Med • 2015

optimizing antiTNFalpha therapy : serum levels of infliximab and adalimumab associate with mucosal healing in patients with inflammatory bowel diseases

B Ungar, I Levy, Y Yavne
Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc • 2015

Subcutane - ous golimumabmaintains clinical response in patients with moderatetosevere ulcerative colitis

WJ Sandborn, BG Feagan, C Marano

Similar Papers

Loading similar papers…